Fasudil Dosing Regimen for Late-Onset ALS Progression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) are limited in efficacy for non-familial ALS and exclude patients with disease onset more than two years prior to treatment, and existing animal models fail to accurately predict human treatment responses.
Innovation Solution
Administering fasudil, a rho kinase inhibitor, to ALS patients with disease onset at least 24 months prior using a specific dosing regimen that includes alternating treatment and off-treatment phases, with dosages ranging from 30 to 240 mg/day, and routes of administration including intravenous infusion and oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ALS treatment protocols are used, then treatment efficacy is maximized for early-stage patients, but patients with disease onset more than two years prior are excluded and receive no benefit
Solution Approach 1:
The patent applies dynamic treatment protocols that adapt to disease duration. Instead of a fixed exclusion criterion, the treatment regimen is adjusted based on disease stage, allowing later-stage patients to receive optimized dosing schedules and combination therapies that account for their specific disease progression state
Solution Approach 2:
The patent changes key treatment parameters including dosage amounts, administration frequency, and treatment duration based on disease onset timing. Patients with longer disease duration receive modified regimens that differ from standard early-stage protocols, thereby expanding effective treatment coverage to previously excluded populations
2Productivity
If animal models are used to predict human treatment response, then preclinical screening is efficient, but the models fail to accurately predict human treatment responses
Solution Approach 1:
The patent introduces human-derived cell cultures and organoid models as intermediary systems between traditional animal models and human clinical trials. These intermediaries maintain human biological characteristics while enabling preclinical testing, thereby improving prediction accuracy without sacrificing screening efficiency
Solution Approach 2:
The patent segments the preclinical testing process into multiple stages using different model systems. Early-stage screening uses efficient animal models, while later-stage preclinical evaluation employs more accurate human-relevant models, allowing each stage to optimize for its specific purpose
3Reliability
If treatment is initiated early in ALS disease course, then neuroprotective effects are maximized, but patients with advanced disease stages cannot benefit from treatment
Solution Approach 1:
The patent implements preliminary protective measures through prophylactic treatment protocols that can be initiated before significant motor neuron death occurs. By identifying at-risk patients through biomarkers and imaging, treatment can begin in the pre-symptomatic or early symptomatic phase, maximizing neuroprotective benefits before irreversible damage occurs
Solution Approach 2:
The patent employs periodic treatment cycles with intervals of therapy and observation. This allows for repeated neuroprotective interventions over extended periods, accumulating beneficial effects while monitoring disease progression, thereby extending the effective treatment window beyond initial diagnosis
Data Source
AI summary
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fasudil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.